Home - Articial Pancreas
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-177,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive



Continuous glucose monitoring provides accurate real-time blood glucose measurements and reveals trends that en able proactive therapeutic interventions to maintain glycaemic control. With an artificial pancreas, a computer program, instead of the person with diabetes, calculates how much insulin the pump delivers based on readings from a continuous glucose monitor.

Users have the option to make dosing adjustments in certain situations, but the device mostly acts automatically to keep blood glucose levels within a target range. The technology has been shown to facilitate good glucose control and holds the promise to alleviate the disease burden improving the life of a person with diabetes substantially.




1. CGM Sensor

A sensor is inserted under the skin to continuously measure glucose.

2. CGM Receiver

A CGM receiver displays the glucose readings minute by minute as values, graph and trend.

3. Control algorithm device

Readings are sent to a control algorithm device (CAD) – e.g. a smartphone – where an algorithm analyses them and calculates the most appropriate insulin dose.

4. Insulin pump

The CAD communicates with a body-worn insulin pump that administers the correct insulin dose via a cannula inserted under the skin. Items 2 and 3 can be integrated with the insulin pump.



Jort Kropff (1986) was born in Enkhuizen, the Netherlands. As a curious little guy he was determined to become a policeman, inventor, no a salesman before eventually making up his mind, he wanted to become a physician. Fascinated by the function of the human mind and body he thoroughly enjoyed medical school.


Already in the early years of his training Kropff defended the students interest at the student council, the medical schools’ program management and the national education audit committee. That experience brought his passion for people and interest in policy making together. During an internship at the University of Oxford he published his first scientific paper about genetic causes of diabetes. Shortly before the completion of medical school he started his PhD-training at the department of internal medicine, under the supervision of Professor J.H. de Vries and Professor J.B.L. Hoekstra. He is proud to have been part of an initiative that aims to alleviate the burden of people living with diabetes.


During his PhD-program, Kropff started a Master of Business Administration for healthcare managers, funded by the University of Amsterdam and the Academic Medical Centre. After defending his thesis, he aims to start his training in internal medicine and hopes to contribute to more personalized healthcare.